N-acetylcysteine attenuates cardiopulmonary bypass-induced lung injury in dogs

Xianfeng Qu¹, Qianyu Li¹, Xiaofei Wang¹*, Xiaoping Yang¹ and Dongguo Wang²*

Abstract

Background: Cardiopulmonary bypass (CPB) is usually associated with inflammatory response that leads to various degrees of organ dysfunction in multiple systems, including lung injury. Our previous study showed that transforming growth factor beta1 (TGFβ1) was involved in CPB-induced lung injury. N-acetylcysteine (NAC) is an antioxidant and is able to prevent CPB-induced pneumocyte apoptosis through scavenging radical. Therefore, we investigated whether NAC may attenuate CPB-induced lung injury by inhibiting TGFβ1 expression.

Methods: Fifty-four 18 to 24-month-old mongrel dogs (15–16 kg) were randomly divided into control group, CPB group and NAC group (n = 18). Six dogs in each group were killed prior to, as well as 30 and 60 minutes after the operation (T0, T1 and T2). Lung injury was evaluated by hematoxylin and eosin (H&E) staining. Respiratory index (RI), oxygenation index (OI), malondialdehyde (MDA) content and superoxide dismutase (SOD) activity in the lung were determined at each time point. TGFβ1 expression was determined using real time RT-PCR and immunohistochemistry.

Results: A serious lung injury was observed after CPB in dogs. RI and MDA content were increased significantly after CPB, whereas OI and SOD activity were decreased. H&E staining showed that NAC treatment obviously attenuated CPB-induced lung injury. NAC treatment upregulated OI and SOD activity and downregulated RI and MDA content in the lung tissues of dogs after CPB. Treatment with NAC significantly suppressed the TGFβ1 expression in the lung tissues at both mRNA and protein levels.

Conclusion: Our results suggest that NAC is a potent agent against CPB-induced acute lung injury through inhibiting TGFβ1 expression.

Keywords: N-acetylcysteine, Cardiopulmonary bypass, Respiratory distress syndrome, Adult

Background

Cardiopulmonary bypass (CPB), which is an essential technique for cardiac surgery, usually induces acute lung injury [1]. Lung injury clinically affects a small number of patients who undergo CPB. It is part of the CPB-induced organ dysfunction that may cause a collapsed lung and may develop into acute respiratory distress syndrome (ARDS) [1]. Therefore, CPB-induced acute lung injury is one of the main reasons for death after cardiac surgery [2].

Transforming growth factor beta1 (TGFβ1), a cytokine with complex functions, is able to regulate cell growth, proliferation and differentiation, and participate in the inflammatory response and tissue repair [3-6]. It has been reported that TGFβ1 participates in the endotoxin-induced acute lung injury through TGFβ1-Smad3 pathway [7]. TGFβ1 is abundantly expressed in the bronchoalveolar lavage fluid of the patients with ARDS during the early stage [8]. In our previous work, we also found the expression of TGFβ1 was upregulated in CPB-induced acute lung injury in dogs. It can directly increase the permeability of pulmonary artery endothelial cells and alveolar epithelial cells, resulting in the formation of pulmonary edema, the releasing of proinflammatory cytokines and thereby aggravating lung injury [9-11]. TGFβ1 also participates in the progression of lung fibrosis following injury [12]. Furthermore, TGFβ1 may aggravate the lung injury through increasing endothelial [13] and epithelial permeability [14] and decreasing ion and fluid transport [15,16]. In view of the important role of
TGFβ1 in the development of acute lung injury, inhibition of TGFβ1 may be a potential therapeutic strategy for reducing CPB-induced acute lung injury.

N-acetylcysteine (NAC) is an antioxidant that could scavenge oxygen free radicals with protective effects on cells and microcirculation [17]. NAC is able to alleviate lung reperfusion injury induced by deep hypothermic circulatory arrest through scavenging oxygen free radicals [18]. It can reduce the pulmonary vascular resistance index and decrease the incidence of lung injury after off-pump coronary artery bypass surgery [19]. Interestingly, NAC can also prevent CPB-induced pneumocyte apoptosis through scavenging radical [20]. However, the relationship between NAC treatment and TGFβ1 expression in lung tissues has not been reported. In view of the important role of TGFβ1 during the progression of acute lung injury, the objective of this work was to investigate whether NAC could exert a protective effect on CPB-induced acute lung injury through inhibiting the expression of TGFβ1.

Methods
Animals and experiment design
Fifty-four 18 to 24-month-old mongrel dogs (15 ~ 16 kg) were purchased from the Experimental animal center of Zhejiang University. These dogs were randomly assigned into the control group, CPB group and NAC group (n = 18). Dogs were anesthetized with 2% sodium pentobarbital (i.p., 30 mg · kg⁻¹), placed on a constant-temperature operating table and then endotracheal intubation was carried out. The animal was placed on an AH-II animal ventilator (Beijing science and Technology Development Company, Beijing, China) in the volume control mode. Initial ventilatory settings included: FIO₂ 1.0, delivered tidal volume measured at the endotracheal tube 12 ml · kg⁻¹. The respiratory rate (RR) was adjusted according to the result of blood gas analysis to maintain the PaCO₂ between 35 and 40 mmHg. Mean arterial pressure (MAP) and central venous pressure (CVP) were monitored by an Intellivue MP50type multifunctional monitor (Philips, Holland) through placing femoral arterial and femoral venous catheters. Anesthesia was maintained with a continuous infusion of fentanyl (100 μg · kg⁻¹ · min⁻¹). Intermittent boluses of vecuronium bromide (0.1 mg · kg⁻¹) was administered for neuromuscular blockade. The lung injury after CPB was induced according to the method reported by Williams et al. [21]. Briefly, after a median sternotomy, the pericardium was incised. After administration of heparin (3 mg · kg⁻¹), cannulation was accomplished by placing an 8-French infant arterial cannula in the ascending aorta and a single 22-French venous cannula in the right atrium. Each dog was placed on conventional nonpulsatile CPB at a flow of (125 ml · kg⁻¹ · min⁻¹). Five minutes later, each animal was

![Figure 1 HE staining of lung tissues.](http://www.cardiothoracicsurgery.org/content/8/1/107)
compared with CPB group, respectively.

Table 2 Effect of NAC on the levels of RI and OI

| Group | RI | OI |
|-------|----|----|
|       | T0 | T1 | T2 | T0 | T1 | T2 |
| Control | 0.72 ± 0.03 | 0.74 ± 0.03 | 0.75 ± 0.04 | 422 ± 25 | 417 ± 27 | 420 ± 23 |
| CPB | 0.71 ± 0.04 | 4.71 ± 0.55 | 5.10 ± 0.13 | 420 ± 26 | 272 ± 25 | 220 ± 22 |
| NAC | 0.75 ± 0.04 | 0.79 ± 0.41 | 1.07 ± 0.63 | 425 ± 27 | 318 ± 26 | 306 ± 26 |

Data are expressed as median (range). Compared with control group, a P < 0.05; compared with CPB group, b P < 0.05.

Blood samples were obtained from femoral artery at indicated time points and then RI and OI were analyzed. Data are expressed as means ± S.D (n = 6).

Compared with T0 time point, a P < 0.05; compared with control group, b P < 0.05; compared with CPB group, c P < 0.05.

Briefly, after the lung tissues were rinsed in pre-cool saline to remove the blood, the lung tissues were weighed and homogenized in 9 times the volume of homogenate medium (saline) using a Soniprep150 ultrasonic disintegrator (MSE company, United States). Then the homogenate was centrifuged at 3000 g for 12 min and supernatant was saved. The MDA content and SOD activity were measured with commercial kits from Nanjin Jiancheng Bioengineering Institute (Nanjing, China) using BeckmanDU800 (Beckman company, the United States of America) visible light analyzer.

Hematoxylin and Eosin Staining

Pulmonary tissues were fixed with 4% paraformaldehyde, embedded in paraffin and stained with Hematoxylin and Eosin Staining (H&E) [23]. The images were obtained with a Leica DM1000 optical microscope and the pulmonary injury was scored by a blinded observer according to the following criteria [24]: alveolar congestion, hemorrhage, infiltration or aggregation of neutrophils in the airspace or vessel wall, and thickness of the alveolar wall. Each item was graded according to a 5-point scale: 0, minimal (little) damage; 1, mild damage; 2, moderate damage; 3, severe damage; and 4, maximum damage. Thus, minimum and maximum possible scores were 0 and 16, respectively.

Immunohistochemistry

The expression of TGFβ1 was determined by immuno-histochemical (IHC) staining with a commercial Strept Actavidin-Biotin Complex (SABC) kit (Zhongshan Biological Technology, Beijing, China). IHC was carried out using a specific polyclonal anti- TGFβ1 antibody (1:150, Santa Cruz Biotech, Santa Cruz, CA, USA). The images were obtained with a Leica DM1000 optical microscope and analyzed by the image analysis system, Image-Pro Plus5.1.0.20 (Media Cybernetics, Silver Spring, MD, USA). Five unduplicated fields were selected in one slide.

RNA extraction and semi-quantitative RT-PCR

Total RNA was extracted from pulmonary tissues with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manual. The concentration and purity of total RNA were determined by a spectrophotometer (Eppendorf, Hamburg, Germany). Reverse transcription was performed.
using oligo (dT) primer RT mixtures with M-MLV (Promega, Madison, WI, USA) reverse transcriptase 200 U/20 μl, total RNA 1 μg/20 μl. cDNA was stored at −20°C. Primers used in the PCR reaction were as follows: β-actin, forward: 5′-G T A A A G A C C T A T G CCA ACA -3′, reverse: 5′- CTG GAA GGT GGA CAG TGA G -3′; TGFβ1: forward: 5′–TAA TGG TGG ACC GCA ACA AC -3′, reverse: 5′- GTG AGC ACT GAA GCG AAA GC -3′. PCR reaction was performed with 2 μl of cDNA, 1 u Taq DNA Polymerase (Fermentas, MBI, USA) and 0.5 μmol/L of forward and reverse primers, for a total volume of 20 μl. Reactions were started with a polymerase activation step at 94°C for 1 min followed by 30 cycles of 94°C for 1 min, 54°C for 1 min and 72°C for 1 min, and elongation at 72°C for 10 min. The PCR products were electrophoresed on a 1.5% agarose gel in the presence of ethidium bromide, and absorbance was measured by an image analysis system. The ratio of targets to β-actin was used to evaluate the significance of the difference between the two groups.

Statistical analysis
Statistical significance was determined using SPSS 13.0 for Windows. Measurement data are expressed as means ± S. D. Student’s t-test was performed to detect any differences between the two groups. Count data are expressed as median (range) and the difference in lung injury score between the two groups was tested using Kruskal-Wallis rank sum test. Differences were deemed significant if P < 0.05.

Results
NAC attenuated CPB-induced lung injury
To investigate the effect of NAC on CPB-induced lung injury, H&E staining was performed. As shown in Figure 1, fine structure of lung was observed in the control group, without inflammatory cells infiltration. Smooth and complete pulmonary alveolar wall without bleeding and exudate in the pulmonary alveolar and interstitial was also observed in the lung tissues of control group (Figure 1). In the CPB group, disorder of the structure of lung tissues, and a large amount of fluid and a number of red blood cells in the pulmonary alveolar wall were observed. Marked hyperemia in the pulmonary alveolar wall, thickening of alveolar septa, edema in the pulmonary interstitium, extensive infiltration of inflammatory cells and focal atelectasis were also observed. With the treatment of NAC, the destruction on the lung structure was obviously reduced and little inflammatory cells were observed. The pulmonary injury score of NAC group was much lower than that of CPB group (Table 1).

Table 3 Effect of NAC on the MDA and SOD levels at different time points

| Group   | MDA (nmol/mg) | SOD (U/mg) |
|---------|---------------|------------|
|         | T0            | T1         | T2         | T0            | T1            | T2            |
| Control | 10.5 ± 1.0    | 10.8 ± 1.1 | 10.9 ± 1.2 | 154.7 ± 3.9   | 150.8 ± 4.8   | 151.69 ± 2.7  |
| CPB     | 12.3 ± 1.5    | 25.8 ± 1.9 | 24.9 ± 1.8 | 153.6 ± 4.9   | 76.9 ± 3.8    | 82.2 ± 3.1    |
| NAC     | 11.6 ± 1.0    | 16.5 ± 2.4 | 16.2 ± 2.1 | 150.7 ± 2.2   | 97.3 ± 2.4    | 98.5 ± 3.6    |

Data are expressed as means ± S.D (n = 6). Compared with T0 time point, * P < 0.05, ** P < 0.01; compared with control group, # P < 0.05, ## P < 0.01; compared with CPB group, $ P < 0.05, $$$ P < 0.01.

Figure 2 Expression of TGFβ1 mRNA levels at each time point.
After the dogs were killed at each time points, total RNA of lung was isolated. Semi RT-PCR was performed to detect the TGFβ1 mRNA expression. A. Agarose gel electrophoresis of TGFβ1 and β-actin; B. Quantities for densitometric analysis of TGFβ1 mRNA. Data are expressed as mean ± S.D. (n = 6). ** P < 0.01, compared with control; ### P < 0.01, compared with CPB.
NAC regulated RI and OI post operation
There were no significant changes of RI and OI in control group post operation (Table 2). Compared with the values at T0 time point, RI values of CPB and NAC groups were increased, while OI values were decreased ($P < 0.05$) at T1 and T2 time points. The RI values of NAC group were lower and the OI values of NAC group were higher at T1 and T2 time points than those of CPB group, respectively.

NAC regulated MDA and SOD post operation
The MDA levels and the SOD activity are considered as indicators of lipid peroxidation [25]. Therefore, we examined the MDA content and the SOD activity in the dogs’ lung tissues at different time points (Table 3). There were no obvious changes in MDA content and SOD activity in control group post the operation. The MDA content of lung tissues in CPB group was increased significantly after CPB, while treatment with NAC inhibited the increase of MDA content. In addition, there was a significant decrease of SOD activity in the CPB group at T1 and T2 time points compared with that at T0 time point. However, the decrease of SOD activity was significantly reversed by NAC treatment.

NAC inhibited the TGFβ1 expression in the lung tissues
To investigate the effect of NAC on the expression of TGFβ1 in lung tissues, we performed RT-PCR and immunohistochemistry. The expression of TGFβ1 mRNA increased significantly after CPB compared with those of control (Figure 2). TGFβ1 protein was also overexpressed in the lung tissues of dogs in CPB group after CPB as shown by immunohistochemical staining (Figure 3). Treatment with NAC significantly suppressed the TGFβ1 expression in the lung tissues at both mRNA and protein levels.

Discussions
In the present study, we investigated the effect of NAC on CPB-induced acute lung injury. NAC reduced the pathological injury of the lung tissues in dogs. NAC treatment reversed CPB-induced upregulation of RI and MDA content, and downregulation of OI and SOD activity. CPB-induced expression of TGFβ1 in the lung of dogs was also inhibited by NAC treatment. The results showed that treatment with NAC attenuated the CPB-induced lung injury, indicating that NAC may be a potential drug for CPB-induced lung injury.

MDA is the end-products of lipid peroxidation and is considered as an indicator of the extent of lipid peroxidation, as well as the degree of tissue injury induced by oxygen free radicals. SOD is an oxygen free radical scavenger, reflecting the ability of scavenging oxygen free radicals. NAC, a micromolecule containing active hydrosulfide (−SH) with molecular weight of 163.29 g mol$^{-1}$,
could be quickly absorbed into the cells. As a sulphhydryl donor, it can scavenge oxygen free radicals and play a role in antioxidation directly. In addition, it could be converted to cysteine by stripping acetyl. Cysteine is the precursor of reduced glutathione hormone (GSH) which is able to scavenge oxygen free radicals [26]. Thus, NAC can also exert antioxidant effect indirectly. In the present study, our results showed that the MDA level was upregulated, while the SOD activity was downregulated in the lung tissues of dogs after CPB. In consistent with previous study [20], treatment with NAC significantly improved the lipid peroxidation injury in the lung tissues after CPB, indicating NAC may play a protective role in CPB-induced acute lung injury through its antioxidant effect.

TGFβ1 has been shown to be a critical mediator of acute lung injury [14]. The upregulation of TGFβ1 is usually related with the increase of the permeability of pulmonary endothelial monolayers and the permeability of alveolar epithelial monolayers [8]. The upregulation of TGFβ1 also leads to the decrease of sodium channel ENaC on the apical surface of alveolar epithelial cells [15], subsequently impairing the removal of salt and water from the alveolar lumen. Interestingly, it has also been reported that oxygen free radicals could activate pro-inflammatory nuclear factors, such as NF-κB and AP-1, and subsequently induce the expression of TGFβ1 [27-30]. Therefore, increased oxygen free radicals level in the injured lung tissues after CPB potentially lead to the upregulation of TGFβ1. Furthermore, TGFβ1 could promote the release of oxygen free radicals to form the infernal circle of oxygen free radical-TGFβ1 expression in the lung tissues and thereby blocking the infernal circle of oxygen free radical-TGFβ1-lung injury may be the mechanisms involved in the protective effect of NAC on CPB-induced acute lung injury in dogs.

Conclusion
In conclusion, our results showed that NAC could alleviate the acute lung injury induced by CPB in dogs. The underlying mechanisms include scavenging oxygen free radicals and downregulating TGFβ1 expression in the lung tissues after CPB. Our results suggest that NAC is a potent agent against CPB-induced acute lung injury.

Abbreviations
ARDS: Acute respiratory distress syndrome; CPB: Cardiopulmonary bypass; CVP: Central venous pressure; GSH: Glutathione hormone; H&E: Hematoxylin and eosin; IHC: Immunohistochemical; MDA: Malondialdehyde; MAP: Mean arterial pressure; NAC: N-acetylcysteine; OI: Oxygenation index; RI: Respiratory index; RR: Respiratory rate; SABC: Strept Actavidin-Biotin Complex; SOD: Superoxide dismutase; TGFβ1: Transforming growth factor beta1.

Competing interests
The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

Authors’ contributions
DW designed research; XQ, QL and XX performed research; XY analyzed data; DW and XW wrote the paper. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the Medical Science Foundation of Department of Public Health, Zhejiang Province (2008B3) and the Foundation of science and Technology bureau of Taizhou (909K4Y0).

Received: 1 December 2012 Accepted: 12 April 2013 Published: 22 April 2013

References
1. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg. 1996, 68:1107–1111.
2. Canet J, Gallart L, Gomar C, Paloue G, Vallès J, Castillo J, Sabate S, Mato V, Briones Z, Sanchez J: Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology 2010, 113:1338–1350.
3. Park S, Ahn JY, Lim MJ, Kim MH, Lee SL, Yun YS, Jeong G, Song JY. Im-412 inhibits transforming growth factor beta-induced fibroblast differentiation in human lung fibroblasts. Biochem Biophys Res Commun 2010, 390:268–273.
4. Miyake T, Ali NS, Mckermott KC. Nuclear function of smad7 promotes myogenesis. Mol Cell Biol 2010, 30:722–735.
5. Mishra I, Deynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005, 310:65–71.
6. Wipff PJ, Hinz B. Integrons and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Bio 2008, 87:601–615.
7. Gao J, Zhao WX, Xue FS, Zhou LJ, Xu SQ, Ding N. Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the tgf-beta1-smad2 dependent pathway. Inflamm Res 2010, 59:491–500.
8. Fahy Rl, Lichtenberger F, McKeegan CB, Nuovo GJ, Marsh CB, Wewen MD. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol 2002, 28:499–503.
9. Wesselkamper SC, Case LM, Henning LN, Borchers MT, Tichelar JV, Mason JM, Dragan N, Medvedovic M, Sattor MA, Tomilinson CR, Leekaa GD: Gene expression changes during the development of acute lung injury: Role of transforming growth factor beta. Am J Respir Crit Care Med 2005, 172:1399–1411.
10. Clements RT, Minnear FL, Singer HA, Keller RS, Vincent PA: Rhoa and rho- kinase dependent and independent signals mediate tgf-beta1-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1294–L1306.
11. Birukova AA, Birukov KG, Adyshev D, Usatyuk P, Natarajan V, Garcia JG, Verin AD: Involvement of microtubules and rho pathway in tgf-beta1-induced lung vascular barrier dysfunction. J Cell Physiol 2005, 204:934–947.
12. Broekeleman Tj, Limper Ah, Colby TV, McDonald J: Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991, 88:5662–5666.
13. Hunt Vi, Goldberg PL, Minnear FL, Heirnark RL, Vincent PA: Rearrangement of adherens junctions by transforming growth factor-beta1: Role of contraction. Am J Physiol 1999, 276:L582–L595.
14. Pittet JF, Griffiths MJ, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LA, Gotwals PJ, Koteliauski VE, Matthay MA, Sheppard D. Tgf-beta is a critical mediator of acute lung injury. J Clin Invest 2001, 107:1537–1544.
15. Frank J, Roux J, Kawakatsu H, Su G, Dagenais A, Berthiaume Y, Howard M, Gotwals PJ, Koteliansky VE, Matthay MA, Sheppard D. Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alpha-enac and alveolar epithelial vectorial sodium and fluid transport via an erk1/2-dependent mechanism. J Biol Chem 2003, 278:43939–43950.
16. Willis BC, Kim KJ, Li X, Liebler J, Crandall ED, Borok Z: Modulation of ion conductance and active transport by tgf-beta 1 in alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 2003, 285:L192–L200.
Tossios P, Bloch W, Huebner A, Raji MR, Dodos F, Klass O, Suedkamp M, Kasper SM, Hellmich M, Mehlhorn U: N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2003, 126:1513–1520.

Cakir O, Oruc A, Kaya S, Eren N, Yildiz F, Erdinc L: N-acetylcysteine reduces lung reperfusion injury after deep hypothermia and total circulatory arrest. J Card Surg 2004, 19:221–225.

Kim JC, Hong SW, Shim JK, Yoo KJ, Chun DH, Kwak YL: Effect of n-acetylcysteine on pulmonary function in patients undergoing off-pump coronary artery bypass surgery. Acta Anaesthesiol Scand 2011, 55:462–459.

Klass O, Fischer UM, Antonyan A, Boise M, Fischer JH, Bloch W, Mehlhorn U: Pneumocyte apoptosis induction during cardiopulmonary bypass: effective prevention by radical scavenging using n-acetylcysteine. J Invest Surg 2007, 20:349–356.

Williams EA, Welty SE, Geske RS, Hubble CL, Craig DM, Quick G, Meliones JN, Chefetz IM: Liquid lung ventilation reduces neutrophil sequestration in a neonatal swine model of cardiopulmonary bypass. Crit Care Med 2001, 29:789–795.

Kerbaul F, Van der Linden P, Pierre S, Rondelet B, Melot C, Brimioulle S, Naeije R: Prevention of hemodilution-induced inhibition of hypoxic pulmonary vasoconstriction by n-acetylcysteine in dogs. Anesth Analg 2004, 99:547–551, table of contents.

Mao ZM, Song HY, Yang LL, Liu T, Li DF, Zheng PY, Liu P, Ji G: Effects of the mixture of swertia pseudochinensis hara and silybum marianum gaertn extracts on ccl(4)-induced liver injury in rats with non-alcoholic fatty liver disease. Zhong Xi Yi Jie He Xue Bao 2012, 10:193–199.

Takao Y, Mikawa K, Nishina K, Obara H: Attenuation of acute lung injury with propofol in endotoxemia. Anesth Analg 2005, 100:810–816, table of contents.

Gorgulu A, Kiris T, Unal F, Turkoglu U, Kucuk M, Cobanoglu S: Superoxide dismutase activity and the effects of nbqx and cpp on lipid peroxidation in experimental spinal cord injury. Res Exp Med (Berl) 2000, 199:285–293.

Chapple IL: Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 1997, 24:287–296.

Kwang KY, Literat A, Zhu NL, Huang HH, Li C, Jones CA, Minoo P: Expression of transforming growth factor beta (tgf-beta1) in human epithelial alveolar cells: A pro-inflammatory mediator independent pathway. Life Sci 2004, 74:2941–2957.

Jardine H, MacNee W, Donaldson K, Rahman I: Molecular mechanism of transforming growth factor (tgf)-beta1-induced glutathione depletion in alveolar epithelial cells. Involvement of ap-1/are and fra-1. J Biol Chem 2002, 277:21158–21166.

Manabe E, Handa O, Naito Y, Mizushima K, Akagiri S, Adachi S, Takagi T, Kokura S, Maoka T, Yoshikawa T: Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem 2008, 103:1925–1937.

Itagaki T, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K, Fukuno H, Honda H, Okamura Y, Ito S: Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 2005, 54:1782–1789.